Sicart Associates LLC Increases Stock Position in Merck & Co., Inc. (NYSE:MRK)

Sicart Associates LLC boosted its stake in Merck & Co., Inc. (NYSE:MRK) by 3.9% in the third quarter, HoldingsChannel reports. The firm owned 88,282 shares of the company’s stock after acquiring an additional 3,353 shares during the period. Merck & Co., Inc. makes up approximately 2.5% of Sicart Associates LLC’s holdings, making the stock its 13th largest holding. Sicart Associates LLC’s holdings in Merck & Co., Inc. were worth $7,480,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of MRK. Titan Capital Management LLC CA bought a new stake in shares of Merck & Co., Inc. during the 2nd quarter valued at $25,000. LFA Lugano Financial Advisors SA grew its position in shares of Merck & Co., Inc. by 250.0% during the 2nd quarter. LFA Lugano Financial Advisors SA now owns 315 shares of the company’s stock valued at $26,000 after acquiring an additional 225 shares during the period. JJJ Advisors Inc. bought a new stake in shares of Merck & Co., Inc. during the 2nd quarter valued at $27,000. Cumberland Partners Ltd bought a new stake in shares of Merck & Co., Inc. during the 2nd quarter valued at $40,000. Finally, Fusion Family Wealth LLC grew its position in shares of Merck & Co., Inc. by 268.2% during the 2nd quarter. Fusion Family Wealth LLC now owns 486 shares of the company’s stock valued at $41,000 after acquiring an additional 354 shares during the period. 75.02% of the stock is owned by institutional investors and hedge funds.

MRK has been the subject of a number of recent research reports. Svb Leerink initiated coverage on shares of Merck & Co., Inc. in a research report on Friday, August 16th. They set an “outperform” rating and a $103.00 price objective for the company. Credit Suisse Group reissued a “buy” rating and set a $95.00 price objective on shares of Merck & Co., Inc. in a research report on Wednesday, August 7th. Societe Generale set a $105.00 price objective on shares of Merck & Co., Inc. and gave the company a “buy” rating in a research report on Tuesday, September 3rd. ValuEngine downgraded shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. Finally, Mizuho reissued a “buy” rating and set a $97.00 price objective on shares of Merck & Co., Inc. in a research report on Friday. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and fifteen have assigned a buy rating to the stock. Merck & Co., Inc. presently has an average rating of “Buy” and an average price target of $94.00.

Merck & Co., Inc. stock traded down $0.35 during mid-day trading on Monday, hitting $84.33. The stock had a trading volume of 776,796 shares, compared to its average volume of 7,689,117. The firm has a market capitalization of $214.56 billion, a P/E ratio of 19.43, a P/E/G ratio of 1.96 and a beta of 0.53. The company has a current ratio of 1.21, a quick ratio of 0.92 and a debt-to-equity ratio of 0.82. The firm’s 50 day moving average is $84.37 and its 200 day moving average is $82.31. Merck & Co., Inc. has a one year low of $66.10 and a one year high of $87.35.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, July 30th. The company reported $1.30 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.14. The company had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $10.94 billion. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 43.34%. Merck & Co., Inc.’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.06 EPS. As a group, equities research analysts forecast that Merck & Co., Inc. will post 4.91 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Monday, October 7th. Investors of record on Monday, September 16th were issued a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 2.61%. The ex-dividend date of this dividend was Friday, September 13th. Merck & Co., Inc.’s dividend payout ratio is currently 50.69%.

In related news, EVP Richard R. Deluca sold 6,427 shares of the company’s stock in a transaction on Friday, August 9th. The shares were sold at an average price of $85.09, for a total value of $546,873.43. Following the completion of the transaction, the executive vice president now owns 103,223 shares of the company’s stock, valued at approximately $8,783,245.07. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.27% of the company’s stock.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Recommended Story: What does earnings per share mean?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.